296 related articles for article (PubMed ID: 31618704)
1. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K; Gauler T; Dietz A; Grünwald V; Stöhlmacher J; Knipping S; Schroeder M; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U
Eur J Cancer; 2019 Nov; 122():53-60. PubMed ID: 31618704
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
3. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
Sun Y; Guo W; Bai Y; Ge M; Hu C; Wu S; Hao J; Gao M; Pan J; Dong P; Wu Y; Liang H; Wei Q; Zhong M; Lu T
Oral Dis; 2020 Mar; 26(2):285-294. PubMed ID: 31830347
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
14. Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Goerling U; Gauler T; Dietz A; Grünwald V; Knipping S; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U; Klinghammer K
Oncol Res Treat; 2022; 45(6):319-325. PubMed ID: 34915492
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
18. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
[TBL] [Abstract][Full Text] [Related]
19. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
20. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]